Patrys LimitedASX: PAB

Pipeline Expanded with Proprietary Injectable Antipsychotic

· Issued by Patrys Limited

Filed with ASX · · 8 pages · English

Summary by 6ix AI

Patrys Limited has announced the acquisition of Reliis Pty Ltd, a clinical-stage pharmaceutical company, to expand its pipeline with a proprietary injectable antipsychotic targeting the delirium market. This acquisition aims to reduce development risk and enhance Patrys' portfolio by adding a near-term, lower-risk pharmaceutical asset alongside its existing biologics program. The filing outlines the strategic rationale for the acquisition, emphasizing the potential for accelerated regulatory pathways and value creation for shareholders.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Patrys Limited on 6ix

Earlier from Patrys

Later from Patrys

All Patrys news releases